Ultragenyx Pharmaceutical (RARE) Profit After Tax: 2016-2025
Historic Profit After Tax for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to -$180.4 million.
- Ultragenyx Pharmaceutical's Profit After Tax fell 35.12% to -$180.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$579.8 million, marking a year-over-year decrease of 3.73%. This contributed to the annual value of -$569.2 million for FY2024, which is 6.17% up from last year.
- According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Profit After Tax is -$180.4 million, which was down 56.95% from -$115.0 million recorded in Q2 2025.
- In the past 5 years, Ultragenyx Pharmaceutical's Profit After Tax registered a high of -$73.0 million during Q3 2021, and its lowest value of -$245.1 million during Q3 2022.
- Its 3-year average for Profit After Tax is -$147.5 million, with a median of -$151.1 million in 2025.
- As far as peak fluctuations go, Ultragenyx Pharmaceutical's Profit After Tax crashed by 583.62% in 2021, and later surged by 34.87% in 2023.
- Ultragenyx Pharmaceutical's Profit After Tax (Quarterly) stood at -$122.5 million in 2021, then declined by 23.99% to -$151.8 million in 2022, then rose by 18.86% to -$123.2 million in 2023, then decreased by 8.28% to -$133.4 million in 2024, then plummeted by 35.12% to -$180.4 million in 2025.
- Its Profit After Tax was -$180.4 million in Q3 2025, compared to -$115.0 million in Q2 2025 and -$151.1 million in Q1 2025.